Collectively, these data indicate that concomitant suppression of the antiapoptotic protein Bcl-xL, thereby “freeing” BIM, is needed for a robust apoptotic response after KRASG12C inhibition in KRASG12CMT colorectal cancer. The gene discussed is BCL2L11; the disease is colorectal cancer.